Enhancing Recovery after Radical Prostatectomy
At Levee Medical®, we are committed to designing solutions that aim to reduce complications associated with surgical treatment.
One in 8 men will develop prostate cancer*
Patients often choose surgery to treat prostate cancer
In most cases, surgery enables complete and immediate removal of cancer.
Urinary incontinence after prostatectomy remains a debilitating problem
It is the most feared complication following surgery for prostate cancer.
Life after prostatectomy deserves to be brilliant
Our goal is to minimize incontinence so that patients can turn the page after prostate cancer surgery.
Introducing
Voro® Urologic Scaffold
Transforming prostatectomy recovery with the first and only absorbable device specifically engineered to address urinary incontinence head-on.
PUBLICATIONS
Initial Experience with an Absorbable Urologic Scaffold to Mitigate Early Urinary Incontinence following Radical Prostatectomy: A Report of 2 Cases, Urologia Internationalis
The Levee Medical Voro prostatectomy implant is not approved for sale worldwide. It is not FDA-cleared or approved. It is currently in the research and development phase and is not available for sale in any country.
Content is intended for healthcare professionals.
Team
Bruce Choi
Founder, Director, CTO & Chairman
Adam Irving
CEO & Director
Kevin Hopkins
Vice President, Quality
Karen Cornett
Vice President, Clinical Affairs
Sean Collins
Vice President,
Market Development
Mike McKellar
Corporate Controller
Mike Henson
Director
Gary McCord
Director
Peter Mulrooney
Director
News
Levee Medical® Announces First Patient Enrolled in ARID II IDE Pivotal Trial
Durham, NC – April 24, 2025 – Levee Medical®, a medical device company focused on improving outcomes for prostate cancer surgery patients, today announced the enrollment of the first patient in its landmark ARID II pivotal trial. This marks a significant milestone in...
Levee Medical Receives FDA Approval for its Landmark ARID II IDE Pivotal Study
Multicenter, randomized controlled pivotal study to investigate a novel device for post-radical prostatectomy stress urinary incontinence Durham, NC – March 4, 2025 – Levee Medical is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted...
Levee Medical® Secures $10 Million in Oversubscribed Series B Funding
Funding to Advance Voro® Urologic Scaffold Development and Clinical Studies Durham, NC – February 11, 2025 – Levee Medical®, a medical device company focused on improving outcomes for prostate cancer surgery patients, announced the successful close of its Series B...
Levee Medical® to Accelerate Development of its Voro® Urologic Scaffold, Designed to Improve Post-Prostatectomy Recovery Outcomes
Additionally, Company Reaches Significant Enrollment Milestones in Feasibility and Observational Studies Durham, NC – June 10, 2024 – Levee Medical®, a medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today...